CN100421718C - Chinese medicinal composition for treating endometriosis and its preparation method - Google Patents
Chinese medicinal composition for treating endometriosis and its preparation method Download PDFInfo
- Publication number
- CN100421718C CN100421718C CNB2004100339549A CN200410033954A CN100421718C CN 100421718 C CN100421718 C CN 100421718C CN B2004100339549 A CNB2004100339549 A CN B2004100339549A CN 200410033954 A CN200410033954 A CN 200410033954A CN 100421718 C CN100421718 C CN 100421718C
- Authority
- CN
- China
- Prior art keywords
- medicine
- radix
- curcumae
- chinese medicine
- rhizoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 201000009273 Endometriosis Diseases 0.000 title claims abstract description 33
- 239000000203 mixture Substances 0.000 title claims description 19
- 238000002360 preparation method Methods 0.000 title claims description 13
- 239000003814 drug Substances 0.000 claims abstract description 71
- 239000002994 raw material Substances 0.000 claims abstract description 10
- 238000011282 treatment Methods 0.000 claims description 40
- 241000237903 Hirudo Species 0.000 claims description 18
- 238000005303 weighing Methods 0.000 claims description 6
- 239000004615 ingredient Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 2
- 238000002481 ethanol extraction Methods 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 17
- 239000008280 blood Substances 0.000 abstract description 17
- 229960000766 danazol Drugs 0.000 abstract description 11
- 230000001737 promoting effect Effects 0.000 abstract description 6
- 102000008946 Fibrinogen Human genes 0.000 abstract description 5
- 108010049003 Fibrinogen Proteins 0.000 abstract description 5
- 229940012952 fibrinogen Drugs 0.000 abstract description 5
- 230000035935 pregnancy Effects 0.000 abstract description 5
- 230000017531 blood circulation Effects 0.000 abstract description 4
- 230000004087 circulation Effects 0.000 abstract description 4
- 210000003743 erythrocyte Anatomy 0.000 abstract description 3
- 208000002193 Pain Diseases 0.000 abstract description 2
- 230000003908 liver function Effects 0.000 abstract description 2
- 230000005906 menstruation Effects 0.000 abstract description 2
- 230000036407 pain Effects 0.000 abstract description 2
- 230000001105 regulatory effect Effects 0.000 abstract description 2
- 230000008961 swelling Effects 0.000 abstract 2
- 235000014375 Curcuma Nutrition 0.000 abstract 1
- 244000164480 Curcuma aromatica Species 0.000 abstract 1
- 241000545744 Hirudinea Species 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 241000270666 Testudines Species 0.000 abstract 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 231100000957 no side effect Toxicity 0.000 abstract 1
- 235000005412 red sage Nutrition 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 23
- 230000000242 pagocytic effect Effects 0.000 description 17
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 241000700159 Rattus Species 0.000 description 13
- 208000005171 Dysmenorrhea Diseases 0.000 description 10
- 206010013935 Dysmenorrhoea Diseases 0.000 description 10
- 239000000796 flavoring agent Substances 0.000 description 10
- 235000019634 flavors Nutrition 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 208000021267 infertility disease Diseases 0.000 description 9
- KFGOFTHODYBSGM-IJCBKZNRSA-N 6-Keto-prostaglandin F1a Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC(=O)CCCCC(O)=O KFGOFTHODYBSGM-IJCBKZNRSA-N 0.000 description 7
- 210000005259 peripheral blood Anatomy 0.000 description 7
- 239000011886 peripheral blood Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 108010002350 Interleukin-2 Proteins 0.000 description 6
- 210000004696 endometrium Anatomy 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 210000002540 macrophage Anatomy 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 208000010669 pelvic lump Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 230000010354 integration Effects 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 244000178320 Vaccaria pyramidata Species 0.000 description 4
- 235000010587 Vaccaria pyramidata Nutrition 0.000 description 4
- 210000001015 abdomen Anatomy 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000003024 peritoneal macrophage Anatomy 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 210000003038 endothelium Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229940126678 chinese medicines Drugs 0.000 description 2
- 210000004081 cilia Anatomy 0.000 description 2
- 230000027326 copulation Effects 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 230000000762 glandular Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000000110 microvilli Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 241000218176 Corydalis Species 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 108010017480 Hemosiderin Proteins 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 244000248825 Peltandra virginica Species 0.000 description 1
- 235000001188 Peltandra virginica Nutrition 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 238000000280 densification Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000012137 double-staining Methods 0.000 description 1
- 201000005311 drug allergy Diseases 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 210000000497 foam cell Anatomy 0.000 description 1
- 210000000569 greater omentum Anatomy 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 208000037922 refractory disease Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000009286 sanguis draxonis Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000004739 secretory vesicle Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- -1 tabletting Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- DNYWZCXLKNTFFI-UHFFFAOYSA-N uranium Chemical compound [U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U] DNYWZCXLKNTFFI-UHFFFAOYSA-N 0.000 description 1
- 238000011121 vaginal smear Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The medicine of the present invention is prepared from 8 raw materials of common prism tuber, zedoray rhizome, red sage root, curcuma root, radix paeoniae rubra, turtle shell, orange fruit and leech, and has the efficiency of promoting blood circulation for removing blood stasis, promoting the circulation of qi, removing swelling and removing stasis. The medicine can alleviate pain by regulating vital energy and promoting blood circulation, remove swelling by absorbing clots and removing stasis, and assist fetation by resolving depression and regulate menstruation. The medicine can obviously reduce blood viscosity, plasma fibrinogen and packed red blood cells of patients of endometriosis, and thereby, the pelvic cavity circulation is improved. Compared with western medicine-Danocrine, the medicine can make the sterile patient have high pregnancy rate; if the medicine is taken in a long term, the medicine has no side effects, such as damaging liver function.
Description
Invention field
The present invention relates to a kind of Chinese medicine composition for the treatment of endometriosis, the present invention also relates to the preparation method of this Chinese medicine composition.
Background technology
Endometriosis is common gynecological disease, frequently-occurring disease, also is one of gynecological's refractory disease, and its sickness rate is in rising trend.The primary disease clinical manifestation is dysmenorrhea, infertile, pelvic cavity tuberosity or enclosed mass etc.Chinese medicine thinks, it is periodically hemorrhage that endometriosis is that ectopic inner membrance has, and accumulates in the part, and cause its surrounding tissue fibrosis, and this is " blood circulating out of vessels ", claims blood-retention or blood stasis.Its sick position is at the part of the body cavity below the umbilicus, housing the bladder, kidneys and bowels, and uterus, collaterals of the uterus are disease.Its basic pathogenesis is exactly a stagnation of blood stasis.There are many Chinese medicine compositions to be used for the treatment of endometriosis in the prior art.Disclosed " medicine for endometriosis " electuary among the CN 1076365A for example, it is to be made by Rhizoma Cyperi, Rhizoma Corydalis, Ramulus Cinnamomi, Radix Salviae Miltiorrhizae, rhizoma sparganic, Rhizoma Curcumae.CN 139723A discloses a kind of compound treatment endometriosis, and it is to be made by Radix Tripterygii Wilfordii, rhizoma sparganic and Rhizoma Curcumae.Jin Jiling discloses " Liaoning Journal of Traditional Chinese Medicine " 1994,21 (6) the 6th pages and has added flavor cassia twig tuckahoe pill for curing endometriosis, and it is made up of 12 flavor Chinese medicines such as rhizoma sparganic, Rhizoma Curcumae, Radix Paeoniae, Radix Salviae Miltiorrhizae, Ramulus Cinnamomi, Poria, but effective percentage has only 83.2%.Chang Nuan etc. disclose FUTONGNING at " Journal of Traditional Chinese Medicine " 1997,38 (8) 488-490 pages or leaves, it by Sanguis Draxonis, Rhizoma Curcumae, rhizoma sparganic, Radix Salviae Miltiorrhizae, Carapax Trionycis, etc. 9 flavor Chinese medicines form.The inventor is at " Journal of Traditional Chinese Medicine " 1995, disclose cowherb rib mixture in 36 (5) the 296-294 pages or leaves, it is to be restrained by rhizoma sparganic, each 6 gram of Rhizoma Curcumae, Radix Salviae Miltiorrhizae, Radix Paeoniae Rubra, Bulbus Fritillariae Thunbergii, each 15 gram of Carapax Trionycis, Radix Curcumae, each 12 gram of Fructus Aurantii, Endothelium Corneum Gigeriae Galli, each 10 gram of Radix Angelicae Sinensis, Hirudo 4.5.The total effective rate of its treatment endometriosis reaches 81.0%.However, its curative effect is still not ideal enough.For this reason, the inventor studied in a basic enterprising step of cowherb rib mixture, the prescription flavour of a drug is simplified, and adjust the consumption of each medicine, thereby improve curative effect, reduced side effect, also was more conducive to the preparation and the quality control of Chinese patent medicine.Through a large amount of screening and experiments, the inventor is surprised to find that and through the experimentation checking flavour of a drug is reduced to 8 flavors by 11, and adjust the consumption of flavour of a drug, especially reduce the consumption of Hirudo, can obtain than Rhizoma Curcumae mixture better therapeutic, total effective rate reaches 90.8%, also greatly reduces side effect simultaneously, thereby has finished the present invention.
Goal of the invention
The purpose of this invention is to provide a kind of littler Chinese medicine composition of endometriosis better efficacy side effect for the treatment of.
Another object of the present invention provides the preparation method of this Chinese medicine composition.
Summary of the invention
Medicine of the present invention is made up of effective ingredient and/or pharmaceutically acceptable excipient, and wherein said effective ingredient is to be made by the raw material of Chinese medicine of following consumption:
Rhizoma Curcumae 8-15%, rhizoma sparganic 8-15%, Radix Salviae Miltiorrhizae 14-20%, Radix Curcumae 10-15%, Carapax Trionycis 14-20%, Radix Paeoniae Rubra 14-20%, Hirudo 2-5% and Fructus Aurantii 10-15%.
In order to obtain better therapeutic, the consumption of preferred raw material of Chinese medicine is: Rhizoma Curcumae 9-12%, rhizoma sparganic 9-12%, Radix Salviae Miltiorrhizae 15-18%, Radix Curcumae 11-14%, Carapax Trionycis 15-18%, Radix Paeoniae Rubra 15-18%, Hirudo 3-4% and Fructus Aurantii 11-14%.
In order to obtain optimum curative effect, more preferably the consumption of raw material of Chinese medicine is: Rhizoma Curcumae 10%, rhizoma sparganic 10%, Radix Salviae Miltiorrhizae 16.7%, Radix Curcumae 13.3%, Carapax Trionycis 16.7%, Radix Paeoniae Rubra 16.7%, Hirudo 3.3% and Fructus Aurantii 13.3%.
The method for preparing medicine of the present invention can be Rhizoma Curcumae, rhizoma sparganic, Radix Salviae Miltiorrhizae, Radix Curcumae, Carapax Trionycis, Radix Paeoniae Rubra, Hirudo and the Fructus Aurantii that takes by weighing above-mentioned consumption, and directly with the dry levigation of raw material of Chinese medicine difference, mixing is made powder.Also above-mentioned raw material of Chinese medicine can be extracted and refining carry or the 60-80% ethanol extraction, reclaim or concentrated, make various dosage forms such as capsule, tablet, granule, oral liquid etc. with pharmaceutically acceptable excipient as water.
Chinese medicine composition of the present invention is further to improve prescription on the basis of cowherb rib mixture, rhizoma sparganic, Rhizoma Curcumae, Radix Salviae Miltiorrhizae, Radix Paeoniae Rubra, Bulbus Fritillariae Thunbergii, Carapax Trionycis, Radix Curcumae, Fructus Aurantii, Endothelium Corneum Gigeriae Galli, Radix Angelicae Sinensis and Hirudo 11 flavors are reduced Bulbus Fritillariae Thunbergii, Endothelium Corneum Gigeriae Galli and Radix Angelicae Sinensis, become rhizoma sparganic, Rhizoma Curcumae, Radix Salviae Miltiorrhizae, Radix Curcumae, Radix Paeoniae Rubra, Carapax Trionycis, Fructus Aurantii and Hirudo 8 flavors, wherein monarch drug is Rhizoma Curcumae and rhizoma sparganic; Ministerial drug is Radix Salviae Miltiorrhizae and Radix Curcumae; Adjuvant drug is Carapax Trionycis, Radix Paeoniae Rubra and Hirudo; Messenger drug is a Fructus Aurantii.Increase the consumption of monarch drug, strengthened blood circulation promoting and blood stasis dispelling, reduced the untoward reaction that brings thus with the function of Xiao Disorder eliminating stagnation reduces the consumption of adjuvant drug Hirudo.Through the adjustment of prescription, medicine flavour of a drug of the present invention are simplified, and effect is strengthened, and the effective percentage of process clinical verification treatment endometriosis rises to 90.8% by the effective percentage 80% of cowherb rib mixture, and untoward reaction obviously reduces.
Medicine of the present invention has the effect of blood circulation promoting and blood stasis dispelling, circulation of qi promoting, Xiao Disorder eliminating stagnation, it is pain relieving by vital energy regualting and blood circulation-promoting, blood stasis-eliminating and stagnation-dissipating Er Xiao Disorder, resolving depression regulating menstruation and gravidity assisting, can significantly reduce endometriosis patient's blood viscosity, plasma fibrinogen, packed cell volume, thereby improve pelvic cavity circulation.Compare with the Western medicine danazol, improve dysmenorrhea effect and endometriosis patients serum EMAb negative conversion rate there was no significant difference, but make the pregnancy rate of infertile patient be relatively higher than danazol, and this medicine takes side effect such as no liver function damage for a long time, thereby be better than danazol.
Specific embodiment
Embodiment 1: capsular preparation
Take by weighing Rhizoma Curcumae 9g, rhizoma sparganic 9g, Radix Salviae Miltiorrhizae 15g, Radix Curcumae 12g, Carapax Trionycis 15g, Radix Paeoniae Rubra 15g, Hirudo 3g and Fructus Aurantii 12g, be dried respectively, levigation, mix homogeneously incapsulates.
Embodiment 2: the preparation of tablet
Take by weighing Carapax Trionycis 16g and decoct with water 20 minutes, add Rhizoma Curcumae 10g, rhizoma sparganic 8g, Radix Salviae Miltiorrhizae 14g, Radix Curcumae 15g, Radix Paeoniae Rubra 17g, Hirudo 3g and Fructus Aurantii 17g again, decoct jointly twice, collecting decoction is condensed into thick paste, adds starch and granulates, add magnesium stearate, tabletting, coating.
Embodiment 3: the preparation of granule
Take by weighing Rhizoma Curcumae 8g, rhizoma sparganic 15g, Radix Salviae Miltiorrhizae 16g, Radix Curcumae 13g, Carapax Trionycis 15g, Radix Paeoniae Rubra 15g, Hirudo 3g and Fructus Aurantii 15g, add 70% alcohol reflux 10-20 hour, reclaim ethanol, be condensed into thick paste, add starch and granulate.
The effect of 1 pair of rat experiment temper of test example endometriosis disease
1 material:
Animal: the female sexual maturity of cleaning level is the Wistar rat of copulation not, and body weight 180-220g is provided by Zhongshan Medical Univ.'s Experimental Animal Center.The quality certification number: the moving word 26-98A011 of doctor.Cleaning level environment is raised.
Reagent: TXB
2, 6-keto-PGF
1The α radioimmunological kit is provided by Yangzhou Medical Science College.The IL-2 radioimmunological kit is provided by East Asia, Beijing immunological technique institute.Alsever solution, interim preparation.
Irritate the stomach medication: with medicine of the present invention be mixed with 30% respectively, 7.5% two kind of concentration.Danazol is produced by Yangzhou, Jiangsu pharmaceutical factory, lot number: 970102.Medicine is made into 1% concentration.All preserve standby in 4 ℃ of refrigerators.
Test method
2.1 the foundation of animal model: concrete grammar is as follows: (1) selects the not female rats of copulation of healthy mature for use, regularly carry out vaginal smear examination every day, selected oestrous cycle 4-5 days and had continuously the rat of two normal oestrous cycles, in the rutting period of the 3rd oestrous cycle, with the rat modeling that undergos surgery respectively.(2) operation is under aseptic condition, with 3% pentobarbital sodium 1.5mm/kg intraperitoneal anesthesia, cutting open the belly behind the routine disinfection cuts a cross-talk palace at place, angle, palace, right side, is about 1 centimetre, be placed in the normal saline rapidly and separate, isolated endometrium is cut into two of 5mm * 5mm size, epithelial layer is oppositely facing to body wall, solid on stomach wall with piece of tissue four angle seams, about each one, give gentamycin normal saline solution flushing abdominal cavity before closing abdomen, successively close abdomen at last, cleaning level environment is raised.Cut open the belly once more after (3) 4 weeks and observe the graft upgrowth situation, being masked as successfully of perform the operation: the increase of graft volume, fluid accumulation appears, and mortifier is by connective tissue and omentum majus covering, and vascularization is arranged.Getting graft simultaneously send the real inner membrance of disease probatio inspectionem pecuoarem to survive.
2.2 grouping is a medication: the model winner is divided into four groups at random: model control group, medicine high concentration group of the present invention, medicine low concentration group of the present invention, danazol group.The medication group is the beginning of 31 days after modeling administration all, and wherein the high and low dose group gives 30%, 7.5% concentration liquid respectively, and every day is all by 5.6ml/kg, the danazol group is pressed 4.2ml/kg every day and is irritated stomach, model control group normal saline every day 3ml irritates stomach, and other establishes 10 of normal rats, the conventional raising.Medicine low dose group of the present invention and danazol dosage be all by unit bodies surface area Equivalent Conversion, altogether administration January.
2.3 index detection method: TXB
2, 6-keto-PGF
1α.Measure: get whole blood 4ml and place and contain 2%EDTA-Na
2The anticoagulant plastic test tube in, 4 ℃ of centrifugal separation plasmas are got serum and are placed below-4 ℃ and preserve.Assay method is with reference to the medicine box description.IL-2 measures: get peripheral blood 2ml, after waiting in the injecting tube to solidify, provoke blood coagulation, place 4 ℃ centrifugal, get supernatant and place cryogenic refrigerator to preserve.Assay method is referring to the test kit description.
The peritoneal fluid macrophage phagocytic function is measured: adopt and partly engulf phagocytic index and the phagocytic percentage that method is observed peritoneal macrophage in the chicken red blood cell body.With reference to " guidance of herbal pharmacology experimental technique ", count 200 macrophages, and calculate phagocytic index and phagocytic percentage, the CRBC/ macrophage number (gulping down) that phagocytic index=quilt is engulfed by following formula; Phagocytic percentage=engulf macrophage number/200 macrophage numbers (gulp down and do not gulp down) 100% of CRBC.
Pathological section: routine pathology section preparation method.Cut dystopy endometrium piece, with 10% formaldehyde fixed, conventional dehydration, paraffin embedding, HE dyeing, light microscopy checking.The piece of tissue of getting is all cut into slices in the maximum gauge place.
Electron microscopic observation: the electron microscope specimen preparation method prepares specimen routinely.Piece of tissue is accomplished 1mm
3Fritter is fixed 3 hours in 2.5% glutaraldehyde and 2% paraformaldehyde mixed liquor, after 0.1M phosphoric acid buffer rinsing 3 times, place 1% Osmic acid. solution to fix 1.5 hours; The buffer rinsing of the same method, with the acetone soln ladder dehydration of variable concentrations, Epon812 soaks into, embedding, polymerization; Embedded block is located the back ultrathin section under light microscopic, cut into slices with uranium, plumbous double staining, places the ultrastructure of tissues observed piece under the JEM-1200EX transmission electron microscope.
2.4 statistical method: paired data adopts the t check, rate relatively use u-test.All statistical works all as calculated machine adopt SPSS for Windows (ver 6.0) software to carry out statistical analysis to handle.
3 results
3.1 TXB to endometriosis rat peripheral blood
2, 6-keto-PGF
1α.Influence: the TXB of rat peripheral blood after the modeling
2Content obviously descends (P＜0.05), 6-keto-PGF
1α.Content descends more obvious (P＜0.01), 6-keto-PGF
1α./ TXB
2Ratio with make film before compare obvious reduction, both compare difference utmost point significance (P＜0.01).After the random packet administration, each administration group is compared TXB with model group
2Content all increases, and serves as obvious (P＜0.01) with medicine low dose group of the present invention especially wherein; Each administration group 6-keto-PGF
1α.Content all obviously increases (P＜0.01), 6-keto-PGF than model group
1α/TXB
2Ratio rise, each administration group is compared difference with model group have significance (P＜0.01).The results are shown in Table 1.
Table 1 is respectively organized rat TXB
2, 6-keto-PGF
1The variation comparison of α (X ± s)
| Group | Mus number (only) | TXB 2(pg/ml) | 6-keto-PGF 1α (pg/ml) | 6-keto-PGF 1α /TXB 2 |
| Before the modeling | 70 | 572.38±189.68 | 141.87±40.09 | 0.268±0.123 |
| After the modeling | 60 | 455.29±158.62 | 54.58±30.50 | 0.143±0.065 |
| The high dose of medicine of the present invention | 15 | 543.57±120.52 * | 143.67±20.47 * * | 0.278±0.083 ** |
| The low dosage of medicine of the present invention | 13 | 572.13±110.13 ** | 139.82±54.09 * * | 0.275±0.077 ** |
| Danazol | 15 | 509.43±104.43 * | 127.67±54.13 * * | 0.262±0.134 ** |
| Model group | 15 | 427.21±160.96 | 50.59±22.02 | 0.124±0.043 |
With comparison before the modeling, P＜0.01, compare with model group,
*P＜0.05,
*P＜0.01
3.2 influence: peripheral blood IL-2 content obviously raise before than modeling (P＜0.01) after the modeling to endometriosis rat peripheral blood IL-2.After the administration, medicine high and low dose group of the present invention and danazol group peripheral blood content obviously descend than model group, analyzing and processing by statistics, and difference all has highly significant (P＜0.05), does not have significance (P＞0.05) and compare difference before each administration group and the modeling.The results are shown in table 2.
The variation that table 2 is respectively organized rat peripheral blood IL-2 is (X ± s) relatively
| Group | Mus number (only) | IL-2(ng/ml) |
| Before the modeling | 70 | 5.54±1.15 |
| After the modeling | 60 | 7.82±1.55 |
| The high dose of medicine of the present invention | 15 | 4.74±0.92 * |
| The low dosage of medicine of the present invention | 13 | 4.31±0.53 * |
| Danazol | 15 | 4.20±0.64 * |
| Model group | 15 | 7.79±1.25 |
With comparison before the modeling, P＜0.01, compare with model group,
*P＜0.05
3.3 the influence to endometriosis rat abdominal cavity macrophage phagocytic function: the peritoneal macrophage phagocytic percentage and the phagocytic index of model control group all obviously increase than normal group, and both compare difference and have utmost point significance (P＜0.01).Especially obviously reduce with the peritoneal macrophage phagocytic percentage and the phagocytic index of danazol and high dose group in each group after the administration, comparing difference with model control group has significance (P＜0.05).Though the low dose group phagocytic percentage descends to some extent, no statistical significance (P＞0.05), its phagocytic index then relatively have obvious reduction (P＜0.05) with model control group.The results are shown in Table 3.
The influence of table 3 pair peritoneal macrophage phagocytic function (X ± s)
| Group | Mus number (only) | Phagocytic percentage (%) | Phagocytic index |
| The normal control group | 10 | 28.1±3.72 | 1.09±0.25 |
| Model control group | 10 | 38.4±5.77 | 1.92±0.13 |
| The high dose of medicine of the present invention | 15 | 30.3±3.58 * | 1.27±0.44 * |
| The low dosage of medicine of the present invention | 13 | 35.2±4.41 | 1.35±0.18 |
| Danazol | 15 | 32.4±4.23 * | 1.28±0.33 * |
With comparison before the modeling, P＜0.01, compare with model group,
*P＜0.05
3.4 influence: the inner membrance survival that visible model group is transplanted under the light microscopic and along the stomach wall superficial growth to endometriosis rat pathological tissue form, form zigzag or annular enclosed structure, the obvious hypertrophy of superficial epithelium becomes column, and have that folliculus is swollen to be formed, body of gland is slot-shaped and high column, and it is cubic that glandular epithelium is, a matter densification, can see a large amount of hemosiderin cells and foam cell in the lumen of gland, rich blood vessel.See after the administration that respectively organizing the Ectopic Endometrium tissue is slot-shaped change, superficial epithelium is short cubic, and cyst is most of to disappear, visible atrophy body of gland, and vascular surface reduces, and Interstitial cell is little and sparse.
3.5 to the Ultrastructural influence of endometriosis rat Ectopic Endometrium: the visible Ectopic Endometrium surface epithelial cell of Electronic Speculum drag group has flourishing microvillus and elongated cilium, abundant organelle is arranged in the endochylema, as Golgi body, ribosome, mitochondrion etc., visible lysosome and secretory granule.And the thin surperficial microvillus of the visible Ectopic Endometrium epithelium of each administration group is short and small sparse, almost can not see cilium, and karyon is big, profile is irregular, and endochylema is few, and the Golgi body in the endochylema, DNA mitochondrial DNA quantity obviously reduce, dilatation of rough endoplasmic reticula, and the granule of taking off phenomenon is arranged, in addition visible a large amount of apoptotic body.Especially change obviously with high dose group and danazol group in each administration group.
Test example 2
Clinical data: endometriosis diagnostic criteria and dysmenorrhea integration standard are all determined by " the new Chinese medicine treatment endometriosis of pelvis clinical research guideline " of Ministry of Public Health promulgation.
Include standard in: allly meet the endometriosis diagnostic criteria and all can include in.
Exclusion standard: (1) is associated with serious disease patients such as hysteromyoma, cardiovascular and cerebrovascular vessel, liver, kidney and hemopoietic system, psychotic; (2) dysmenorrhea that causes by other reasons, infertile or pelvic lump, tuberosity person; (3) do not meet the standard of including in, not medication in accordance with regulations, incomplete, can't judge curative effect person drug allergy or data.
Select endometriosis patient that January to 1998 nineteen ninety-five, year December was confirmed at Guangdong Provincial TCM Hospital endometriosis training totally 97 examples, be divided into treatment group 65 example and matched group 32 examples at random by the prescription on individual diagnosis order.33.4 ± 5.8 years old treatment group mean age; Dysmenorrhea person's 32 examples.Infertile person's 19 examples, pelvic lump, tuberosity person 33 examples.33.7 ± 6.4 years old matched group mean age, dysmenorrhea person's 19 examples.Infertile person's 13 examples, pelvic lump, tuberosity person 24 examples.Credit is analysed by statistics, and two groups of patient's age, symptom distribution situation are all suitable, have comparability (P＞0.05) between two groups.
Treatment and observational technique
The treatment group: medicine of the present invention, oral, every day 3 times, each 6; Matched group: danazol (Jiangsu Rieter pharmaceutical factory product) is oral, every day 2 times, each 0.2 gram.Treatment is 6 months continuously.During the treatment, two groups of other medicines of all stopping using.
Observation index: before and after the treatment, two groups of patients' main clinical manifestation is as dysmenorrhea integration, pelvic lump or tuberosity size and infertile patient pregnancy rate; The negative conversion rate of two groups of patients serum EMAb; Treatment group whole blood viscosity, Fibrinogen and hemorheology index change.
Criterion of therapeutical effect and result
" revised standard " by the 3rd academic conference of CAIM (Chinese Association Of Integrative Medicine) department of obstetrics and gynecology Professional Committee.
Result: treatment group 9 examples of fully recovering, produce effects 17 examples, effective 33 examples, invalid 6 examples, cure-remarkable-effectiveness rate 40.0%, total effective rate 90.8%.Matched group 2 examples of fully recovering, produce effects 11 examples, effective 13 examples, invalid 6 examples, cure-remarkable-effectiveness rate 40.6%, total effective rate 81.3%.Two groups of cure-remarkable-effectiveness rates and total effective rate difference do not have significance (P＞0.05).
Influence to the endometriosis dysmenorrhea integration: treatment group 30 example is calculated dysmenorrhea integrations before and after the treatment, and is average 10.17 ± 2.29 before the treatment, treatment back 5.34 ± 3.53, and the dysmenorrhea integration difference before and after the treatment of treatment group has utmost point significance (P＜0.01).
Influence to endometriosis infertile patient gestation situation: infertile person's 19 examples, 9 examples of becoming pregnant after the treatment are organized in treatment; Infertile person's 13 examples of matched group, 1 example of becoming pregnant after the treatment.Treatment group pregnancy rate is significantly higher than matched group (P＜0.05).
Influence to endometriosis patient pelvic lump size (three radial line sums): person's 33 examples that have the enclosed mass in the treatment group, average out to 14.83 ± 4.12cm before treating treats back average out to 11.86 ± 4.38cm; Person's 24 examples that have the enclosed mass in the matched group, average out to 15.76 ± 4.85cm before treating treats back average out to 9.22 ± 4.63cm.The pelvic lump size all has significant difference (P all＜0.01) before and after two groups of treatments, but treatment back matched group is significantly less than treatment group (P＜0.05).
Influence to endometriosis patients serum EMAb negative conversion rate: positive 27 examples of EMAb before the treatment group is treated, 14 examples of turning out cloudy after the treatment, negative conversion rate 51.9%; Positive 16 examples of EMAb before matched group is treated, 9 examples of turning out cloudy after the treatment, negative conversion rate 56.3%.Two groups of negative conversion rate comparing differences do not have significance (P＞0.05).
To the rheol influence of endometriosis blood samples of patients: medicine of the present invention can obviously reduce vital energy stagnation and blood stasis type endometriosis patient whole blood specific viscosity (height is cut) and blood plasma specific viscosity (P all＜0.01), reduces fibrinogen content and packed cell volume (P all＜0.01) in the blood plasma.See attached list 1.
The variation of hemorheology index before and after the treatment of table 1 treatment group (X ± S)
| The example number | Before the treatment | After the treatment | |
| Whole blood specific viscosity (height is cut) (mPa.s) | 65 | 5.40±0.59 | 4.56±0.90 * |
| Whole blood specific viscosity (low cutting) (mPa.s) | 65 | 7.69±1.23 | 7.22±1.26 |
| Blood plasma specific viscosity (height is cut) (mPa.s) | 65 | 1.89±0.21 | 1.77±0.14 * |
| Fibrinogen (g/L) | 65 | 3.01±1.25 | 2.51±0.76 * |
| Erythrocyte is built up index | 65 | 1.51±0.22 | 1.42±0.25 |
| Packed cell volume (%) | 65 | 41.47±3.18 | 38.37±3.97 * |
*With preceding relatively P＜0.01 of treatment.
Claims (5)
1. a Chinese medicine composition for the treatment of endometriosis is made up of effective ingredient and pharmaceutically acceptable excipient, and wherein said effective ingredient is to be made by the raw material of Chinese medicine of following consumption:
Rhizoma Curcumae 8-15%, rhizoma sparganic 8-15%, Radix Salviae Miltiorrhizae 14-20%, Radix Curcumae 10-15%, Carapax Trionycis 14-20%, Radix Paeoniae Rubra 14-20%, Hirudo 2-5% and Fructus Aurantii 10-15%.
2. according to the described Chinese medicine composition of claim 1, wherein the raw material consumption is: Rhizoma Curcumae 9-12%, rhizoma sparganic 9-12%, Radix Salviae Miltiorrhizae 15-18%, Radix Curcumae 11-14%, Carapax Trionycis 15-18%, Radix Paeoniae Rubra 15-18%, Hirudo 3-4% and Fructus Aurantii 11-14%.
3. according to the described Chinese medicine composition of claim 2, wherein the raw material consumption is: Rhizoma Curcumae 10%, rhizoma sparganic 10%, Radix Salviae Miltiorrhizae 16.7%, Radix Curcumae 13.3%, Carapax Trionycis 16.7%, Radix Paeoniae Rubra 16.7%, Hirudo 3.3% and Fructus Aurantii 13.3%.
4. the preparation method of claim 1 or 2 or 3 described Chinese medicine compositions is characterized in that taking by weighing Rhizoma Curcumae, rhizoma sparganic, Radix Salviae Miltiorrhizae, Radix Curcumae, Carapax Trionycis, Radix Paeoniae Rubra, Hirudo and Fructus Aurantii, and with the dry levigation of above-mentioned raw material of Chinese medicine difference, mixing is made.
5. the preparation method of claim 1 or 2 or 3 described Chinese medicine compositions, it is characterized in that taking by weighing Rhizoma Curcumae, rhizoma sparganic, Radix Salviae Miltiorrhizae, Radix Curcumae, Carapax Trionycis, Radix Paeoniae Rubra, Hirudo and Fructus Aurantii, decocting boils or the 60-80% ethanol extraction, reclaims or concentrates, and makes various dosage forms with pharmaceutically acceptable excipient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100339549A CN100421718C (en) | 2004-04-21 | 2004-04-21 | Chinese medicinal composition for treating endometriosis and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100339549A CN100421718C (en) | 2004-04-21 | 2004-04-21 | Chinese medicinal composition for treating endometriosis and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1689614A CN1689614A (en) | 2005-11-02 |
| CN100421718C true CN100421718C (en) | 2008-10-01 |
Family
ID=35345568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100339549A Expired - Lifetime CN100421718C (en) | 2004-04-21 | 2004-04-21 | Chinese medicinal composition for treating endometriosis and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100421718C (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113125763A (en) * | 2019-12-31 | 2021-07-16 | 江苏康缘药业股份有限公司 | Application of combination marker in preparation of evaluation product for effect of cassia twig and poria cocos capsules on treatment of primary dysmenorrhea |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1081107A (en) * | 1992-03-16 | 1994-01-26 | 山东青岛中西医结合医院 | Medicine for endometriosis and manufacturing process thereof |
-
2004
- 2004-04-21 CN CNB2004100339549A patent/CN100421718C/en not_active Expired - Lifetime
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1081107A (en) * | 1992-03-16 | 1994-01-26 | 山东青岛中西医结合医院 | Medicine for endometriosis and manufacturing process thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1689614A (en) | 2005-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104547486A (en) | Traditional Chinese medicine preparation for treating anemia and qi-deficiency weakness and preparation process for traditional Chinese medicine preparation | |
| CN102397328B (en) | Traditional Chinese medicine composition used for treating fractures, preparation method thereof, and application thereof | |
| CN104491733A (en) | Application of traditional Chinese medicine preparation in preparation of medicines for treating anemia, deficiency of vital energy and debilitation | |
| CN103341092A (en) | Preparation method of powder for treating atrophic vaginitis | |
| CN100421718C (en) | Chinese medicinal composition for treating endometriosis and its preparation method | |
| CN102861192B (en) | Medicine composition for chronic renal failure and peritoneal fibrosis | |
| CN103585539A (en) | Traditional Chinese medicine composition for treating climacteric syndrome | |
| CN1319555C (en) | Medicine for treating prostate hyperplasia and method of preparing the same | |
| CN103285284A (en) | Medical composition for treating senile vaginitis | |
| CN103301353A (en) | Pharmaceutical composition for treating atrophic vaginitis | |
| CN103405708B (en) | Drug for treating chronic enteritis and preparation method thereof | |
| CN105362645A (en) | Preparation method of pharmaceutical composition for treating oral inflammations | |
| CN105232691A (en) | Traditional Chinese medicine preparation for promoting caesarean section wound healing and preparation method of traditional Chinese medicine preparation | |
| CN104825715B (en) | It is a kind of to be used to prevent and treat Chinese medicine composition of urarthritis and its preparation method and application | |
| CN104258175A (en) | Traditional Chinese medicine for treating kidney calculi and preparation method thereof | |
| CN109793826A (en) | A kind of Chinese medicine composition for treating fracture of children | |
| CN103301373A (en) | Pharmaceutical composition for treating postpartum perineal mucosal lesions | |
| CN103330867A (en) | Preparation method of powder for treating senile vaginitis | |
| CN1251723C (en) | Pharmaceutical composition for treating idiopathic thrombocytopenic purpura of blood heat type and its preparing process | |
| CN110215474B (en) | Traditional Chinese medicine composition for promoting blood circulation to remove blood stasis and application thereof | |
| CN101279084B (en) | Chinese medicine for treating chronic pelvic inflammatory disease and preparation method thereof | |
| CN105770815A (en) | Folium artemisiae argyi-containing traditional Chinese medicine composition for treating postpartum collapse and preparation method thereof | |
| CN104547504A (en) | Heat-clearing and yin-nourishing rice bran oil as well as preparation method and application thereof | |
| CN103316270A (en) | Preparation method of powder of medicine for treating postnatal perineum mucosal lesion | |
| CN103071125A (en) | Traditional Chinese medicament composition for treating endometriosis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: KANGMEI PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: HOSPITAL NO.2 ATTACHED TO GUANGZHOU TRADITIONAL CHINESE MEDICINE UNIV Effective date: 20110512 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 510120 NO. 111, DADE ROAD, GUANGZHOU CITY, GUANGDONG PROVINCE TO: 515300 CHANGCHUN ROAD, PUNING CITY, JIEYANG CITY, GUANGDONG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20110512 Address after: 515300 Changchun Road, Puning, Guangdong, Jieyang Patentee after: KANGMEI PHARMACEUTICAL Co.,Ltd. Address before: Guangzhou City, Guangdong province 510120 Dade Road No. 111 Patentee before: THE SECOND AFFILIATED HOSPITAL OF GUANGZHOU University OF CHINESE MEDICINE |
|
| CX01 | Expiry of patent term |
Granted publication date: 20081001 |
|
| CX01 | Expiry of patent term |